Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ligand Pharmaceuticals, a biotechnology company, and Trevena, a drug discovery company, have initiated a joint research and licensing alliance to screen targets using Trevena's novel biological platform against Ligand's combinatorial library of compounds, to identify active compounds with potential for development as novel G-protein coupled receptor therapeutics.
Subscribe to our email newsletter
Under the terms of the agreement, Trevena has received exclusive worldwide rights to sublicense active compounds resulting from the collaboration. Ligand expects to screen 24 targets over two years and receive payments triggered by a tiered screening paradigm for each target.
John Higgins, president and CEO of Ligand, said: “We are delighted to enter into this collaboration that allows us to generate cash flow from the combinatorial chemistry technology we gained through our acquisition of Pharmacopeia. Working closely with the Trevena team, we hope to rapidly identify and advance novel drug candidates using their unique insight into G-protein coupled receptor therapeutics signaling pathways.”